Agents in development for the treatment of diabetic nephropathy

Su Yen Goh; Mariusz Jasik; Mark E. Cooper

doi:10.1517/14728214.13.3.447

Agents in development for the treatment of diabetic nephropathy

Su Yen Goh, Mariusz Jasik, Mark E. Cooper

Research output: Contribution to journal › Review Article › Research › peer-review

15 Citations (Scopus)

Abstract

Background: Nephropathy is a major cause of morbidity and mortality in diabetic patients. Current treatments include optimization of glycemic and blood pressure control, but more innovative strategies are needed for the prevention and treatment of diabetic nephropathy. Objectives: To review emerging therapies for diabetic nephropathy. Methods: This paper discusses the molecular mechanisms of diabetic nephropathy and the potential therapeutic interventions. Results/conclusion: New therapies, including those targeting the accumulation of advanced glycation end products (AGEs) and reactive oxygen species (ROS) generation, are likely to feature in future treatment regimens. Other approaches that at this stage do not appear to be progressing include the glycosaminoglycan sulodexide and the protein kinase C-beta (PKC-β) inhibitor, ruboxistaurin.

Original language	English
Pages (from-to)	447-463
Number of pages	17
Journal	Expert Opinion on Emerging Drugs
Volume	13
Issue number	3
DOIs	https://doi.org/10.1517/14728214.13.3.447
Publication status	Published - 1 Sep 2008
Externally published	Yes

Keywords

Advanced glycation
Complications
Diabetes mellitus
Diabetic nephropathy
Glycosaminoglycans
Growth-factors
Protein kinase C inhibition
Renin-angiotensin-aldosterone system

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1517/14728214.13.3.447

Cite this

@article{c981ed155e0d408bb8d9a9e3105715ce,

title = "Agents in development for the treatment of diabetic nephropathy",

abstract = "Background: Nephropathy is a major cause of morbidity and mortality in diabetic patients. Current treatments include optimization of glycemic and blood pressure control, but more innovative strategies are needed for the prevention and treatment of diabetic nephropathy. Objectives: To review emerging therapies for diabetic nephropathy. Methods: This paper discusses the molecular mechanisms of diabetic nephropathy and the potential therapeutic interventions. Results/conclusion: New therapies, including those targeting the accumulation of advanced glycation end products (AGEs) and reactive oxygen species (ROS) generation, are likely to feature in future treatment regimens. Other approaches that at this stage do not appear to be progressing include the glycosaminoglycan sulodexide and the protein kinase C-beta (PKC-β) inhibitor, ruboxistaurin.",

keywords = "Advanced glycation, Complications, Diabetes mellitus, Diabetic nephropathy, Glycosaminoglycans, Growth-factors, Protein kinase C inhibition, Renin-angiotensin-aldosterone system",

author = "Goh, {Su Yen} and Mariusz Jasik and Cooper, {Mark E.}",

year = "2008",

month = sep,

day = "1",

doi = "10.1517/14728214.13.3.447",

language = "English",

volume = "13",

pages = "447--463",

journal = "Expert Opinion on Emerging Drugs",

issn = "1472-8214",

publisher = "Taylor & Francis",

number = "3",

}

TY - JOUR

T1 - Agents in development for the treatment of diabetic nephropathy

AU - Goh, Su Yen

AU - Jasik, Mariusz

AU - Cooper, Mark E.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Background: Nephropathy is a major cause of morbidity and mortality in diabetic patients. Current treatments include optimization of glycemic and blood pressure control, but more innovative strategies are needed for the prevention and treatment of diabetic nephropathy. Objectives: To review emerging therapies for diabetic nephropathy. Methods: This paper discusses the molecular mechanisms of diabetic nephropathy and the potential therapeutic interventions. Results/conclusion: New therapies, including those targeting the accumulation of advanced glycation end products (AGEs) and reactive oxygen species (ROS) generation, are likely to feature in future treatment regimens. Other approaches that at this stage do not appear to be progressing include the glycosaminoglycan sulodexide and the protein kinase C-beta (PKC-β) inhibitor, ruboxistaurin.

AB - Background: Nephropathy is a major cause of morbidity and mortality in diabetic patients. Current treatments include optimization of glycemic and blood pressure control, but more innovative strategies are needed for the prevention and treatment of diabetic nephropathy. Objectives: To review emerging therapies for diabetic nephropathy. Methods: This paper discusses the molecular mechanisms of diabetic nephropathy and the potential therapeutic interventions. Results/conclusion: New therapies, including those targeting the accumulation of advanced glycation end products (AGEs) and reactive oxygen species (ROS) generation, are likely to feature in future treatment regimens. Other approaches that at this stage do not appear to be progressing include the glycosaminoglycan sulodexide and the protein kinase C-beta (PKC-β) inhibitor, ruboxistaurin.

KW - Advanced glycation

KW - Complications

KW - Diabetes mellitus

KW - Diabetic nephropathy

KW - Glycosaminoglycans

KW - Growth-factors

KW - Protein kinase C inhibition

KW - Renin-angiotensin-aldosterone system

UR - http://www.scopus.com/inward/record.url?scp=53549090148&partnerID=8YFLogxK

U2 - 10.1517/14728214.13.3.447

DO - 10.1517/14728214.13.3.447

M3 - Review Article

C2 - 18764722

AN - SCOPUS:53549090148

VL - 13

SP - 447

EP - 463

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 3

ER -

Agents in development for the treatment of diabetic nephropathy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Research output

Agents in development for the treatment of diabetic nephropathy

Cite this